A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

• Status: Recruiting
• Trial end date: 2023-05-30
• Target enrollment: 0
• Participant gender: All

Summary

A Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase 2 Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aristea Therapeutics, Inc.

Criteria

Inclusion Criteria:

• At least 6 months history of moderate or severe PPP, as defined by PPPASI ≥12 and PPPGA ≥3 at screening

• Males and females must be willing to use birth control as indicated

Exclusion Criteria:

• Moderate to severe psoriasis covering ≥10% of total body surface area (BSA) at screening

• Breastfeeding or pregnant

• Known immunodeficiency or subject is immunocompromised

• Active/latent infection with HBV, HCV, HIV, SARS-CoV-2 or TB

• Any topical medications for PPP excluding emollients within two weeks of randomization and systemic therapies (including phototherapy) within 4 weeks of randomization